New Drug Doubles Survival Time for Pancreatic Cancer

Scientists have finally cracked a genetic mutation once thought impossible to treat, potentially transforming outcomes for 90% of pancreatic cancer patients.

A new drug targeting KRAS mutations has doubled survival time compared to traditional chemotherapy.